GERN Quote, Financials, Valuation and Earnings

Biogen, Inc. has a net margin of -39.02% compared to Geron Corp.'s net margin of 19%. Geron Corp.'s return on equity of -29.65% beat Biogen, Inc.'s return on equity of 9.36%.

Geron Corp. has a consensus price target of $3.50, signalling upside risk potential of 162.47%. On the other hand Biogen, Inc. has an analysts' consensus of $178.76 which suggests that it could fall by -1.77%. Given that Geron Corp. has higher upside potential than Biogen, Inc., analysts believe Geron Corp. is more attractive than Biogen, Inc..

Geron Corp. has a beta of 0.567, which suggesting that the stock is 43.26% less volatile than S&P 500. In comparison Biogen, Inc. has a beta of 0.128, suggesting its less volatile than the S&P 500 by 87.226%.

Geron Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biogen, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Geron Corp. pays -- of its earnings as a dividend. Biogen, Inc. pays out -- of its earnings as a dividend.

Geron Corp. quarterly revenues are $47.2M, which are smaller than Biogen, Inc. quarterly revenues of $2.5B. Geron Corp.'s net income of -$18.4M is lower than Biogen, Inc.'s net income of $466.5M. Notably, Geron Corp.'s price-to-earnings ratio is -- while Biogen, Inc.'s PE ratio is 16.60x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Geron Corp. is 4.61x versus 2.75x for Biogen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals, Inc. has a net margin of -39.02% compared to Geron Corp.'s net margin of -255.85%. Geron Corp.'s return on equity of -29.65% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.

Geron Corp. has a consensus price target of $3.50, signalling upside risk potential of 162.47%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -19.81%. Given that Geron Corp. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Geron Corp. is more attractive than NovaBay Pharmaceuticals, Inc..

Geron Corp. has a beta of 0.567, which suggesting that the stock is 43.26% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.

Geron Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Geron Corp. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Geron Corp. quarterly revenues are $47.2M, which are larger than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Geron Corp.'s net income of -$18.4M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Geron Corp.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 1.78x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Geron Corp. is 4.61x versus 2.06x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Ultragenyx Pharmaceutical, Inc. has a net margin of -39.02% compared to Geron Corp.'s net margin of -112.81%. Geron Corp.'s return on equity of -29.65% beat Ultragenyx Pharmaceutical, Inc.'s return on equity of -307.83%.

Geron Corp. has a consensus price target of $3.50, signalling upside risk potential of 162.47%. On the other hand Ultragenyx Pharmaceutical, Inc. has an analysts' consensus of $81.85 which suggests that it could grow by 124.55%. Given that Geron Corp. has higher upside potential than Ultragenyx Pharmaceutical, Inc., analysts believe Geron Corp. is more attractive than Ultragenyx Pharmaceutical, Inc..

Geron Corp. has a beta of 0.567, which suggesting that the stock is 43.26% less volatile than S&P 500. In comparison Ultragenyx Pharmaceutical, Inc. has a beta of 0.162, suggesting its less volatile than the S&P 500 by 83.763%.

Geron Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ultragenyx Pharmaceutical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Geron Corp. pays -- of its earnings as a dividend. Ultragenyx Pharmaceutical, Inc. pays out -- of its earnings as a dividend.

Geron Corp. quarterly revenues are $47.2M, which are smaller than Ultragenyx Pharmaceutical, Inc. quarterly revenues of $159.9M. Geron Corp.'s net income of -$18.4M is higher than Ultragenyx Pharmaceutical, Inc.'s net income of -$180.4M. Notably, Geron Corp.'s price-to-earnings ratio is -- while Ultragenyx Pharmaceutical, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Geron Corp. is 4.61x versus 5.64x for Ultragenyx Pharmaceutical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Cassava Sciences, Inc. has a net margin of -39.02% compared to Geron Corp.'s net margin of --. Geron Corp.'s return on equity of -29.65% beat Cassava Sciences, Inc.'s return on equity of -86.98%.

Geron Corp. has a consensus price target of $3.50, signalling upside risk potential of 162.47%. On the other hand Cassava Sciences, Inc. has an analysts' consensus of $8.00 which suggests that it could grow by 158.07%. Given that Geron Corp. has higher upside potential than Cassava Sciences, Inc., analysts believe Geron Corp. is more attractive than Cassava Sciences, Inc..

Geron Corp. has a beta of 0.567, which suggesting that the stock is 43.26% less volatile than S&P 500. In comparison Cassava Sciences, Inc. has a beta of -1.081, suggesting its less volatile than the S&P 500 by 208.123%.

Geron Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cassava Sciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Geron Corp. pays -- of its earnings as a dividend. Cassava Sciences, Inc. pays out -- of its earnings as a dividend.

Geron Corp. quarterly revenues are $47.2M, which are larger than Cassava Sciences, Inc. quarterly revenues of --. Geron Corp.'s net income of -$18.4M is lower than Cassava Sciences, Inc.'s net income of -$10.8M. Notably, Geron Corp.'s price-to-earnings ratio is -- while Cassava Sciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Geron Corp. is 4.61x versus 2.69x for Cassava Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.